Cancer is the second leading cause of death globally. Although, there are many different
approaches to cancer treatment, they are often painful due to adverse side effects and are …

Defects in apoptosis can promote tumorigenesis and impair responses of malignant B cells
to chemotherapeutics. Members of the B-cell leukemia/lymphoma-2 (BCL-2) family of …

Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing
induction of apoptosis in many cancers. High expression of Mcl-1 causes tumorigenesis and …

Venetoclax (Venclexta™) is an oral selective inhibitor of the prosurvival protein BCL-2 and
therefore restores the apoptotic ability of malignant cells. The drug arose from research by …

Dysregulation of the B-cell leukemia/lymphoma-2 (BCL-2) family of proteins of the intrinsic
apoptotic pathway is fundamental to the pathophysiology of many hematologic …

Dysregulation of the mitochondrial apoptotic pathway controlled by members of the Bcl-2
protein family plays a central role in cancer development and resistance to conventional …

Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous lymphoid malignancy
and the most common subtype of non-Hodgkin's lymphoma in adults, with one of the highest …

High-grade B-cell lymphomas (HGBLs) with MYC and BCL2 and/or BCL6 rearrangements,
so-called “double-hit” lymphomas (HGBL-DH), are aggressive lymphomas that form a …

Acute myeloid leukemia (AML) is a serious disease. The 5-year survival rates remain
frustratingly low (65% for children and 26% for adults). Resistance to frontline chemotherapy …

Since the discovery of apoptosis as a form of programmed cell death, targeting the apoptosis
pathway to induce cancer cell death has been a high-priority goal for cancer therapy. After …